Poliovirus Vaccine Trial Shows Early Promise for Recurrent Glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

View | Comment

Leading Explanations for Whooping Cough's Resurgence Don't Stand Up to Scrutiny

Whooping cough has exploded in the United States and some other developed countries in recent decades, and many experts suspect ineffective childhood vaccines for the alarming resurgence.

View

Lyme Disease Vaccine Shows Promise in Clinical Trial

The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States. Baxter International conducted the clinical trial of the vaccine.

View | Comment

Cutting HPV Vaccine Costs to Poor Countries Should Spur More Vaccinations in US to Prevent Cervical Cancer

View

Preclinical Study Shows Heroin Vaccine Blocks Relapse

Scientists at The Scripps Research Institute (TSRI) have reported successful preclinical tests of a new vaccine against heroin. The vaccine targets heroin and its psychoactive breakdown products in the bloodstream, preventing them from reaching the brain.

View | Comment

Competing Antibodies May Have Limited the Protection Achieved in HIV Vaccine Trial in Thailand

Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.

View | Comment

Focus on STD, Not Cancer Prevention, to Promote HPV Vaccine Use

The HPV vaccine can prevent both cervical cancer and a nasty sexually transmitted disease in women. But emphasizing the STD prevention will persuade more young women to get the vaccine, a new study suggests.

View | Comment

Mayo Clinic Discovers Why Some Don’t Respond to Rubella Vaccine

Using advanced genetic sequencing technology and analysis, Mayo Clinic vaccine researchers have identified 27 genes that respond in very different ways to the standard rubella vaccine, making the vaccine less effective for a portion of the population.

View | Comment

Study Compares Effectiveness of 2 vs. 3 Doses of HPV Vaccine For Girls and Young Women

With the number of doses and cost of human papillomavirus (HPV) vaccines a barrier to global implementation, researchers have found that girls who received two doses of HPV vaccine had immune responses to HPV-16 and HPV-18 infection that were noninferior to (not worse than) the responses for young women who received three doses, according to a study in the May 1 issue of JAMA, a theme issue on child health.

View

St. Jude Experts Available to Discuss H7N9 Avian Influenza

View